Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Yau, T. [1 ]
Meyer, T. [2 ]
Kelley, R. K. [3 ]
Mangeshkar, M. [4 ]
Cheng, A-L. [5 ]
El-Khoueiry, A. B. [6 ]
Abou-Alfa, G. K. [7 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Royal Free Hosp, Oncol, London, England
[3] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[4] Exelixis, Biostat, Alameda, CA USA
[5] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial
    Venerito, Marino
    Abou-Alfa, G. K.
    Mollon, P.
    Meyer, T.
    Cheng, A. -L
    El-Khoueiry, A. B.
    Kelley, R. K.
    Baron, A. D.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 61 - 61
  • [22] Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Trojan, J.
    Abou-Alfa, G. K.
    Mollon, P.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Baron, A. D.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 241 - 241
  • [23] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Waidmann, O.
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A-L
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Merle, P.
    Chen, Y. H.
    Park, J-W
    Blanc, J-F
    Bolondi, L.
    Klumpen, H-J
    Chan, S. L.
    Dadduzio, V
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 254
  • [24] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Chen, Yen-Hsun
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
    Kelley, Robin Kate
    Meyer, Tim
    Rimassa, Lorenza
    Merle, Philippe
    Park, Joong-Won
    Yau, Thomas
    Chan, Stephen L.
    Blanc, Jean-Frederic
    Tam, Vincent C.
    Tran, Albert
    Dadduzio, Vincenzo
    Markby, David W.
    Kaldate, Rajesh
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4795 - 4804
  • [26] Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Meyer, T.
    Cheng, A.
    Cicin, I.
    Bolondi, L.
    Klumpen, H.
    Chan, S.
    Zagonel, V.
    Milwee, S.
    Dubey, S.
    Kelley, R.
    El-Khoueiry, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 33 - 34
  • [27] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC)
    Waidmann, O.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Harris, W. P.
    Nemunaitis, J.
    Olteanu, S.
    Sarker, D.
    Tan, B. R.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 284
  • [28] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Merle, P.
    Rimassa, L.
    Ryoo, B.
    Cicin, I.
    Harris, W.
    Banu, E.
    Sarker, D.
    Tan, B.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 104 - 104
  • [29] Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Mollon, Patrick
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Kelley, Robin Kate
    Baron, Ari David
    Benzaghou, Fawzi
    Valcheva, Velichka Valerieva
    Hazra, Saswati
    Mangeshkar, Milan
    Freemantle, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [30] Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.
    Llovet, Josep M.
    Singal, Amit G.
    Villanueva, Augusto
    Finn, Richard S.
    Kudo, Masatoshi
    Galle, Peter R.
    Wang, Chunxiao
    Widau, Ryan C.
    Gugel, Elena Gonzalez
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345